Insulin resistance and cardiovascular risk factors in patients with mild and severe subclinical hypothyroidism

Endocrinologist

Volumn 20, Issue 3, 2010, Pages 128-130

  Gen, Ramazan ^a   Akbay, Esen ^b   Sezer, Kerem ^b  

^a Erzurum Region Training and Research Hospital   (Turkey)

^b MERSIN UNIVERSITY   (Turkey)

Author keywords

Cardiovascular risk factors; Insulin resistance; Subclinical hypothyroidism

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; THYROTROPIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HOMEOSTASIS; HUMAN; HYPOTHYROIDISM; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; SYSTOLIC BLOOD PRESSURE;

EID: 77952414200     PISSN: 10512144     EISSN: None     Source Type: Journal    
DOI: 10.1097/TEN.0b013e3181dfe618     Document Type: Article

References (29)

1. Cooper DS. Clinical practice. Subclinical hypothyroidism. N Engl J Med. 2001;345:260-265.
2. Biondi B, Cooper DS. The clinical significance of subclinical thyroid dysfunction. Endocr Rev. 2008;29:76-131.
3. Grundy SM, Pasternak R, Greenland P, et al. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation. 1999;100:1481-1492. (Pubitemid 29451714)
4. Luboshitzky R, Aviv A, Herer P, et al. Risk factors for cardiovascular disease in women with subclinical hypothyroidism. Thyroid. 2002;12:421-425.
5. Althaus BU, Staub JJ, Ryff-de Leche A Oberhansli A, et al. LDL/HDL-changes in subclinical hypothyroidism: possible risk factors for coronary heart disease. Clin Endocrinol (Oxf). 1988;28:157-163.
6. Tuzcu A, Bahceci M, Gokalp D, et al. Subclinical hypothyroidism may be associated with elevated high-sensitive c-reactive protein (low grade inflammation) and fasting hyperinsulinemia. Endocr J. 2005;52:89-94.
7. Ozcan O, Cakir E, Yaman H, et al. The effects of thyroxine replacement on the levels of serum asymmetric dimethylarginine (ADMA) and other biochemical cardiovascular risk markers in patients with subclinical hypothyroidism. Clin Endocrinol (Oxf). 2005;63:203-206.
8. Uusitupa MI, Niskanen LK, Siitonen O, et al. 5-year incidence of atherosclerotic vascular disease in relation to general risk factors, insulin level, and abnormalities in lipoprotein composition in non-insulin-dependent diabetic and nondiabetic subjects. Circulation. 1990;82:27-36.
9. Hedblad B, Nilsson P, Engstrom G, et al. Insulin resistance in non-diabetic subjects is associated with increased incidence of myocardial infarction and death. Diabet Med. 2002;19:470-475.
10. Maratou E, Hadjidakis D, Kollias A, et al. Studies of insulin resistance in patients with clinical and subclinical hypothyroidism. Eur J Endocrinol. 2009;160:785-790.
11. Handisurya A, Pacini G, Tura A, et al. Effects of T4 replacement therapy on glucose metabolism in subjects with subclinical (SH) and overt hypothyroidism (OH). Clinl Endocrinol (Oxf). 2008;69:963-969.
12. Dessein P, Joffe B, Stanwix A. Subclinical hypothyroidism is associated with insulin resistance in patients with rheumatoid arthritis. Thyroid. 2004;14:443-446.
13. Sayed AA, Ali NA, Abbas YB, et al. Subclinical hypothyroidism is associated with early insulin resistance in Kuwaiti women. Endocr J. 2006;53:653-657.
14. Gharib H, Tuttle RM, Baskin HJ, et al. Subclinical thyroid dysfunction: a joint statement on management from the American Association of Clinical Endocrinologists, the American Thyroid Association, and the Endocrine Society. Thyroid. 2005;15:24-28. (Pubitemid 40223495)
15. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
16. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and B-cell function from plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-419.
17. Toruner F, Altinova AE, Karakoc A, et al. Risk factors for cardiovascular disease in patient with subclinical hypothyroidism. Adv Ther. 2008;25:430-437.
18. Walsh JP, Bremner AP, Bulsara MK, et al. Thyroid dysfunction and serum lipids: a community-based study. Clin Endocrinol (Oxf). 2005;63:670-675.
19. Hueston WJ, Pearson WS. Subclinical hypothyroidism and the risk of hypercholesterolemia. Ann Fam Med. 2004;2:351-355.
20. Caron P, Calazel C, Parra HJ, et al. Decreased HDL cholesterol in subclinical hypothyroidism: the effect of levothyroxine therapy. Clin Endocrinol (Oxf). 1990;33:519-523.
21. Meier C, Staub JJ, Roth CB, et al. TSH-controlled L-thyroxine therapy reduces cholesterol levels and clinical symptoms in subclinical hypothyroidism: a double blind, placebo controlled trial (basel thyroid study). J Clin Endocrinol Metab. 2001;86:4860-4866.
22. Elder J, McLelland A, O'Reilly DS, et al. The relationship between serum cholesterol and serum thyrotropin, thyroxine and tri-iodothyronine concentrations in suspected hypothyroidism. Ann Clin Biochem. 1990;27:110-113.
23. Pirich C, Mullner M, Sinzinger H. Prevalence and relevance of thyroid dysfunction in 1922 cholesterol screening participants. J Clin Epidemiol. 2000;53:623-629.
24. Bakker SJ, ter Maaten JC, Popp-Snijders C, et al. The relationship between thyrotropin and low density lipoprotein cholesterol is modified by insulin sensitivity in healthy euthyroid subjects. J Clin Endocrinol Metab. 2001;86:1206-1211.
25. Nagasaki T, Inaba M, Kumeda Y, et al. Increased pulse wave velocity in subclinical hypothyroidism. J Clin Endocrinol Metab. 2006;91:154-158.
26. Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836-843.
27. Christ-Crain M, Meier C, Guglielmetti M, et al. Elevated C-reactive protein and homocysteine values: cardiovascular risk factors in hypothyroidism? A cross-sectional and a double-blind, placebo-controlled trial. Atherosclerosis. 2003;166:379-386.
28. Hueston WJ, King DE, Geesey ME. Serum biomarkers for cardiovascular inflammation in subclinical hypothyroidism. Clin Endocrinol (Oxf). 2005;63:582-587.
29. Festa A, D'Agostina R, Mykkanen L, et al. Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance: the Insulin Resistance Atherosclerosis Study (IRAS). Arterioscler Thromb Vasc Biol. 1999;19:562-568.